WHAT IS PAPIG?. WHAT IS PAPIG?  A sub group of SMC.

Slides:



Advertisements
Similar presentations
BLR’s Human Resources Training Presentations
Advertisements

Learning from experience? Getting governments to listen to what evaluations are telling them 23 October 2012 Brian Gleeson, Coordinator General for Remote.
Towards More Effective Board Functioning Fall Lausanne Confidential to CEO-CF and CEO-CF members.
SPOCK My decisions are completely logical. Patient…Elliot analyzing analyzing analyzing analyzing analyzing analyzing.
Definitions Patient Experience Patient experience at NUH results from a range of activities that all impact upon patient care, access, safety and outcomes.
Experiences of Patient and Public involvement in the Research Process Roma Maguire Senior Research Fellow Cancer Care Research Team School of Nursing and.
PATIENT PARTICIPATION GROUPS. Why a patient participation group? Edict from the Care Quality Commission Edict from the Care Quality Commission To ensure.
Evaluate the market research methods used by a selected organisation
What is Monitoring? Information for panellists. Quality assurance of Authority subjects Monitoring poses the question: “How well is the school implementing.
Edinburgh Shadow Strategic Planning Group Wednesday 18 March 2015.
Scottish Medicines Consortium (SMC) User Group Forum Priorities
Patient Interest Seminar 21 st May Dr. Andrew Power Vice Chair New Drugs Sub group.
SMC Evaluation Programme. Overview Context Evaluation Programme –Stakeholders –SMC advice Conclusions.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Educational Solutions for Workforce Development Person- Centred Care.
 Marketing to Non-Profits Making Lasting Impressions Brought to you by The Shawn M. Donnelley Center for Non-Profit Communications.
Managing Up Board Governance from the Staff Perspective © MAP for Nonprofits.
Gender Analyze in Project cycle. The pre-planning stage of a project is the stage when you or your partner organisation start to draw up ideas for a project.
1 The Case Management Approach October 11, 2012 International Centre, Mississauga, ON Suzanne Lepage Private Health Plan Strategist.
Improving Organisational Structure AS Business Studies Unit 2.
TECHNOLOGY APPRAISAL IN ACTION Mrs Karen Samuels Programme Manager.
Dr. Dinesh Kumar Assistant Professor Department of ENT, GMC Amritsar.
Modern Matron/Quality Service Nurse 1st Year Evaluation Report Hilary McCallion - Director of Nursing & Education Elaine Rumble - Deputy Director of Nursing.
SMC Horizon Scanning Anne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline.
Assessment tool OSCE AH Mehrparvar,MD Occupational Medicine department Yazd University of Medical Sciences.
Community Specialist Parkinson’s Nurse Patient Consultation Michael Ellis Stakeholder Engagement Manager Inform the People’s Council on the key findings.
Learning From Patients Engaging Patients in Primary Care Tanya Lord, PhD 1.
The power of information: Putting all of us in control of the health and care information we need Giles Wilmore, Director of Patient & Public Voice and.
Scottish Medicines Consortium SMC RESPONSE TO EVALUATION Angela Timoney Vice Chair SMC 23 rd September 2008.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Scottish Medicines Consortium - Approach to Cancer Medicines Dr Ken Paterson BOPA Symposium 13 September 2007.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
MSc Clinical Research Module 8: Assignment. “There is no effective regulation of post marketing clinical studies” True of False?
Current Challenges and Future Developments in HTA in the UK Frances Macdonald, 23 rd September 2008 (A personal, Industry View)
Sommaire Innovation Summit Roles for Stakeholders in the Healthcare System July 2010.
SMC Evaluation Project The View From Industry Martin Coombes Government Affairs Manager, AstraZeneca ABPI Representative SMC Evaluation Reference Group.
An Introduction to Genetic Alliance UK’s Work in Scotland Natalie Frankish – Development Officer for Scotland Event:Action Duchenne Scottish Conference.
Pharmaceutical companies put forth great effort when identifying their customer needs and wants They then invest in R & D hoping to discover and launch.
Induction toolkit 2. WHAT DOES MY TRUST LOOK LIKE? © GovernWell
SMC and the role of Public Involvement Action Duchenne Scottish Mini Conference 4 December 2015 Lindsay Lockhart Public Involvement Officer.
NATIONAL INITIATIVES: BEST PRACTICE AND LESSONS LEARNED FROM SCOTTISH EXPERIENCE Alan MacDonald Vice Chairman Scottish Medicines Consortium Hard Choices.
Chapter Dental Public Health & Research Contemporary Practice for the Dental Hygienist Copyright ©2011 by Pearson Education, Inc. All rights reserved.
Why the Regular Classroom and Effective Collaboration.
LECTURE 4 WORKING WITH OTHERS. Definition Working with others : is the ability to effectively interact, cooperate, collaborate and manage conflicts with.
`iCARE` Improving our patients, clients and service users experience (with grateful thanks to Yeovil District General Hospital Foundation Trust)
Department of Health The Australian Charter of Healthcare Rights in Victoria Your role in realising the Australian Charter of Healthcare Rights in Victoria.
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.
The Medicines Adherence and Waste Challenge Carol Roberts Director of Strategic Prescribing EAHSN and PrescQIPP.
The Face & Voice of Community Pharmacies in Wales Wyneb a llais o fferyllfeydd cymunedol yng Nghymru Discharge Medicines Review Service The CPW Perspective.
Moving With The Times - Improving Winter Service Delivery - Peter Turland – Steering Group member on behalf of the NWSRG (Adapted from a.
Welcome LEARN: teamwork and communication in Quality Improvement
Patient Involvement in the HTA Decision Making Process
LEADER – Interim results Liz Eyre Rod Hughes Peter Reynolds
Join your surgery’s Patient Participation Group
Management Research
Management Research
Management Research
Ask what matters. Listen to what matters. Do what matters.
Organizational Chart as of February 2017
Prevention. The Care Act 2014 Consultation on draft guidance Prevention, Integration & Cooperation.
Engaging Patients and Families as Partners
Aims objectives of the IAF
Join your surgery’s Patient Participation Group
We are honest and professional with everyone we work with
Workshop Orientation Trade Union Training on
Dignity in Care Charter In Pursuit of Excellence
EU Quality Conferences
Developing a User Involvement Strategy.
RESPONDING TO STUDENT VOICE: PRINCIPLES OF PRACTICE
Presentation transcript:

WHAT IS PAPIG?

WHAT IS PAPIG?  A sub group of SMC

WHAT IS PAPIG?  A sub group of SMC  Members include: 3 Public Partners 1 member of SMC 1 member of ABPI 1 member of NHS Scotland

WHAT DO WE DO?

 Promote public awareness and involvement in SMC WHAT DO WE DO?

 Promote public awareness and involvement in SMC WHAT DO WE DO?  Public Partners provide a summary of the Patient and Carer’s perspective when this has been provided as a Patient Interest Group submission

PATIENT INVOLVEMENT

PATIENT INVOLVEMENT  Involvement of patients in the decision making process is key - PAPIG’s role is to ensure that the views, needs and issues of patients are put before SMC for consideration as part of the process of evaluation of new medicines.

OBJECTIVES FOR THE DAY

OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.

OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland

OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members

OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members  To hear from the Pharmaceutical Industry how drugs are developed and brought to the market.

OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members  To hear from the Pharmaceutical Industry how drugs are developed and brought to the market.  Understand what is needed to make a Patient Interest Group submission to SMC

OBJECTIVES FOR THE DAY  A chance for you to have a greater understanding of the work of SMC and it’s processes and how decisions regarding new medicines are made.  Understand why not all medicines are recommended for use in Scotland  To hear from a Patient Interest Group which has made effective submissions on behalf of their members  To hear from the Pharmaceutical Industry how drugs are developed and brought to the market.  Understand what is needed to make a Patient Interest Group submission to SMC  A chance to ask questions, share ideas and exchange feedback with fellow delegates and today’s presenters.

SUMMARY A good submission will tell SMC:

SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available

SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines

SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer

SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences

SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences  What impact this new medicine is likely to have

SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences  What impact this new medicine is likely to have  The submission is concise, specific and focussed

SUMMARY A good submission will tell SMC:  About patient / carer experiences in respect of medicines currently available  The advantages and disadvantages of these medicines  What patients really need and would prefer  How the new medicine under review matches up to these needs and preferences  What impact this new medicine is likely to have  The submission is concise, specific and focussed  Makes clear any declarations of interest